DE69428791D1 - Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden - Google Patents

Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden

Info

Publication number
DE69428791D1
DE69428791D1 DE69428791T DE69428791T DE69428791D1 DE 69428791 D1 DE69428791 D1 DE 69428791D1 DE 69428791 T DE69428791 T DE 69428791T DE 69428791 T DE69428791 T DE 69428791T DE 69428791 D1 DE69428791 D1 DE 69428791D1
Authority
DE
Germany
Prior art keywords
modafinil
treatment
sleep apnea
pct
breathing difficulties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428791T
Other languages
English (en)
Other versions
DE69428791T2 (de
Inventor
Philippe Laurent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon France SAS
Original Assignee
Laboratoire L Lafon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9448411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69428791(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoire L Lafon SA filed Critical Laboratoire L Lafon SA
Application granted granted Critical
Publication of DE69428791D1 publication Critical patent/DE69428791D1/de
Publication of DE69428791T2 publication Critical patent/DE69428791T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
DE69428791T 1993-06-22 1994-06-14 Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden Expired - Lifetime DE69428791T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9307555A FR2706767B1 (de) 1993-06-22 1993-06-22
PCT/FR1994/000711 WO1995000132A1 (fr) 1993-06-22 1994-06-14 Utilisation du modafinil pour le traitement des apnees du sommeil et troubles ventilatoires d'origine centrale

Publications (2)

Publication Number Publication Date
DE69428791D1 true DE69428791D1 (de) 2001-11-29
DE69428791T2 DE69428791T2 (de) 2002-07-04

Family

ID=9448411

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428791T Expired - Lifetime DE69428791T2 (de) 1993-06-22 1994-06-14 Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden

Country Status (14)

Country Link
US (1) US5612379A (de)
EP (1) EP0705099B1 (de)
JP (1) JP3703831B2 (de)
KR (1) KR100315389B1 (de)
AT (1) ATE207351T1 (de)
AU (1) AU684087B2 (de)
CA (1) CA2165824C (de)
DE (1) DE69428791T2 (de)
DK (1) DK0705099T3 (de)
ES (1) ES2165878T3 (de)
FR (1) FR2706767B1 (de)
HU (1) HU216731B (de)
PT (1) PT705099E (de)
WO (1) WO1995000132A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
WO1999043319A1 (en) 1998-02-27 1999-09-02 The Board Of Trustees Of The University Of Illinois Agents with serotonin-related activity for the treatment for sleep apnea
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
ATE417608T1 (de) * 2000-10-11 2009-01-15 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
MXPA03010705A (es) * 2001-05-25 2004-05-27 Cephalon Inc Formulaciones farmaceuticas solidas que comprenden modafinil.
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
US7528172B2 (en) * 2003-01-21 2009-05-05 The Cooper Health System, Inc. Compositions and methods for improving recovery after general anesthesia
CA2519117C (en) * 2003-03-17 2010-03-02 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR045423A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1586560A1 (de) * 2004-04-13 2005-10-19 Cephalon, Inc. Thio-substituierte Arylmethansulfinyl-Derivate
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
US7314875B2 (en) * 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US7449481B2 (en) * 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
EP1833467B1 (de) * 2004-12-20 2016-08-03 Collegium Pharmaceutical, Inc. Pharmazeutische zusammensetzungen gegen schlafstörungen
CA2614777C (en) * 2005-07-21 2012-04-17 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
CA2660565C (en) * 2006-08-14 2012-10-09 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
WO2008077127A2 (en) * 2006-12-19 2008-06-26 Lavin Thomas N Use of modafinil to treat restless leg syndrome
KR20120101588A (ko) * 2010-01-07 2012-09-13 비버스 인크. 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료
EP3040078B1 (de) 2013-08-30 2021-02-24 Green Cross Wellbeing Corporation Zusammensetzung zur vorbeugung und behandlung von krebsbedingter fatigue mit verarbeitetem ginseng-pulver oder verarbeitetem ginseng-extrakt mit erhöhtem gehalt des bestandteils ginsenosid
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
EP0705099A1 (de) 1996-04-10
HU9503702D0 (en) 1996-02-28
JP3703831B2 (ja) 2005-10-05
US5612379A (en) 1997-03-18
HU216731B (hu) 1999-08-30
EP0705099B1 (de) 2001-10-24
KR960703009A (ko) 1996-06-19
AU684087B2 (en) 1997-12-04
WO1995000132A1 (fr) 1995-01-05
AU7076094A (en) 1995-01-17
KR100315389B1 (ko) 2002-02-19
PT705099E (pt) 2002-03-28
JPH09500374A (ja) 1997-01-14
ATE207351T1 (de) 2001-11-15
DK0705099T3 (da) 2002-02-11
DE69428791T2 (de) 2002-07-04
HUT74674A (en) 1997-01-28
CA2165824A1 (fr) 1995-01-05
ES2165878T3 (es) 2002-04-01
CA2165824C (fr) 2005-08-02
FR2706767B1 (de) 1995-09-08
FR2706767A1 (de) 1994-12-30

Similar Documents

Publication Publication Date Title
DE69428791D1 (de) Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE60207383D1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ATE172963T1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69508192D1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
ATE186305T1 (de) Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE159937T1 (de) 1,4-disubstituierte piperazine zur behandlung von asthma und entzündungen der atemwege
ATE408602T1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
DE69400702D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE59510674D1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE59409813D1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen
ATE177637T1 (de) Triazolochinazoline zur behandlung zentralnervöser erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition